Skip to main content

Tolremo therapeutics AG, the Swiss biotechnology company developing resistance-preventing precision therapies for patients with cancer, announces an additional fundraise bringing the Series A round total to CHF 13.7M.

Male scientist writing elements on glas

This second closing of CHF 4.7M is led by BioMedPartners AG and Altos Ventures AG, who are joining the previous investors Redalpine Venture Partners AG, Zürcher Kantonalbank and experienced private biotech investors.

TOLREMO also announced the appointment of Dr. Reinhard Ambros, former Global Head of the Novartis Venture Fund, as Chairman of the Board as well as Dr. Guido Hartmann, former Head of Pharmacology at Therachon AG (acquired by Pfizer in 2019), as COO/Head Translational Sciences.

The additional funds and new team members will support the development of TOLREMO’s first clinical candidate and further strengthening of the company’s preclinical pipeline of resistance-preventing assets.


For more details, you can have access to the press release here.

Share this article

View all news

Sign up to receive our newsletter in your inbox.